Omnicell, Inc. (NASDAQ:OMCL) Given Consensus Rating of “Buy” by Brokerages

Shares of Omnicell, Inc. (NASDAQ:OMCL) have received an average rating of “Buy” from the twelve analysts that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $79.89.

A number of research analysts recently commented on OMCL shares. Zacks Investment Research raised shares of Triple-S Management from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research report on Monday, April 29th. ValuEngine raised shares of Valmont Industries from a “sell” rating to a “hold” rating in a research report on Friday. BidaskClub downgraded shares of Amyris from a “hold” rating to a “sell” rating in a research report on Thursday, June 27th. Craig Hallum raised shares of PROS from a “hold” rating to a “buy” rating and increased their target price for the company from $36.00 to $60.00 in a research report on Friday, April 26th. Finally, TheStreet downgraded shares of Trinity Industries from a “b” rating to a “c” rating in a research report on Thursday, April 25th.

In other Omnicell news, EVP Nhat H. Ngo sold 4,948 shares of the firm’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $87.08, for a total transaction of $430,871.84. Following the transaction, the executive vice president now directly owns 30,321 shares of the company’s stock, valued at approximately $2,640,352.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Dan S. Johnston sold 9,929 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $85.47, for a total transaction of $848,631.63. Following the transaction, the executive vice president now directly owns 31,505 shares in the company, valued at $2,692,732.35. The disclosure for this sale can be found here. Insiders sold a total of 146,028 shares of company stock worth $10,741,639 over the last ninety days. Insiders own 2.77% of the company’s stock.

A number of institutional investors have recently modified their holdings of OMCL. Parallel Advisors LLC purchased a new position in Omnicell during the 1st quarter worth $28,000. Bronfman E.L. Rothschild L.P. grew its position in Omnicell by 451.8% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 618 shares of the company’s stock worth $38,000 after purchasing an additional 506 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Omnicell by 125.0% during the 1st quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock worth $44,000 after purchasing an additional 300 shares during the last quarter. Manchester Capital Management LLC purchased a new position in Omnicell during the 1st quarter worth $49,000. Finally, Financial Gravity Wealth Inc. purchased a new position in Omnicell during the 1st quarter worth $50,000. 97.30% of the stock is currently owned by institutional investors.

Shares of OMCL traded down $6.50 during midday trading on Tuesday, reaching $68.61. The stock had a trading volume of 1,827,283 shares, compared to its average volume of 469,662. Omnicell has a 1-year low of $52.20 and a 1-year high of $92.59. The business has a fifty day moving average price of $83.41. The firm has a market capitalization of $2.83 billion, a P/E ratio of 44.84, a price-to-earnings-growth ratio of 2.22 and a beta of 1.13. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.47 and a current ratio of 1.96.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, April 25th. The company reported $0.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.38. Omnicell had a net margin of 4.74% and a return on equity of 11.10%. The business had revenue of $202.50 million for the quarter, compared to analyst estimates of $199.72 million. During the same period last year, the business earned $0.29 EPS. The company’s revenue was up 10.9% on a year-over-year basis. Research analysts expect that Omnicell will post 2.06 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Featured Story: What is a short straddle?

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.